Key facts
- Rivus Pharmaceuticals’s last known valuation is $489.0M (Jan 2025).
- It has raised $224.0M across 4 recorded rounds; the latest was Later Stage VC ($57.0M) in Jan 2025.
- Notable investors include RA Capital Management, Longitude Capital, Bain Capital Life Sciences, BB Biotech, Medicxi — 6 tracked in total.
- Rivus Pharmaceuticals has filed 4 Form Ds with the SEC since 2021, most recently Jan 2025 ($57.0M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Rivus Pharmaceuticals
Funding rounds
4 roundsAbout Rivus Pharmaceuticals
Developer of controlled metabolic accelerators designed to improve cardio-metabolic health. The company improves cellular metabolism and treats the underlying cause of highly prevalent metabolic and cardiovascular diseases, enabling patients with oral small-molecule therapeutics that address the underlying metabolic risk factors for cardiovascular mortality and morbidity.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Charlottesville, VA, United States
- Founded
- 2019
- Employees
- 27
- Website
- rivuspharma.com/
- Ownership
- Privately Held (backing)
Rivus Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rivus Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rivus Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.